Picture of ImmuneOnco Biopharmaceuticals (Shanghai) logo

1541 ImmuneOnco Biopharmaceuticals (Shanghai) News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Brief: Immuneonco Biopharmaceuticals Shanghai Says Approval For Phase II Clinical Trial Of IMM2510

Nov 7 (Reuters) - ImmuneOnco Biopharmaceuticals Shanghai
Inc  1541.HK :
    * APPROVAL BY NMPA FOR A PHASE II CLINICAL TRIAL OF IMM2510

Further company coverage:  1541.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on ImmuneOnco Biopharmaceuticals (Shanghai)

See all news